These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 36442722)

  • 1. In vitro evaluation of the gastrointestinal delivery of acid-sensitive pancrelipase in a next generation enteric capsule using an exocrine pancreatic insufficiency disease model.
    Jannin V; Duysburgh C; Gonzalez V; Govaert M; Agisson M; Marzorati M; Madit N
    Int J Pharm; 2023 Jan; 630():122441. PubMed ID: 36442722
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and tolerability of a new formulation of pancrelipase delayed-release capsules (CREON) in children under seven years of age with exocrine pancreatic insufficiency due to cystic fibrosis: an open-label, multicentre, single-treatment-arm study.
    Graff GR; McNamara J; Royall J; Caras S; Forssmann K
    Clin Drug Investig; 2010; 30(6):351-64. PubMed ID: 20441244
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pancrelipase delayed-release capsules (CREON) for exocrine pancreatic insufficiency due to chronic pancreatitis or pancreatic surgery: A double-blind randomized trial.
    Whitcomb DC; Lehman GA; Vasileva G; Malecka-Panas E; Gubergrits N; Shen Y; Sander-Struckmeier S; Caras S
    Am J Gastroenterol; 2010 Oct; 105(10):2276-86. PubMed ID: 20502447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A 6-month, open-label clinical trial of pancrelipase delayed-release capsules (Creon) in patients with exocrine pancreatic insufficiency due to chronic pancreatitis or pancreatic surgery.
    Gubergrits N; Malecka-Panas E; Lehman GA; Vasileva G; Shen Y; Sander-Struckmeier S; Caras S; Whitcomb DC
    Aliment Pharmacol Ther; 2011 May; 33(10):1152-61. PubMed ID: 21418260
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of protection and release behavior of different capsule polymer combinations based on L. acidophilus survivability and function and caffeine release.
    Marzorati M; Calatayud M; Rotsaert C; Van Mele M; Duysburgh C; Durkee S; White T; Fowler K; Jannin V; Bellamine A
    Int J Pharm; 2021 Sep; 607():120977. PubMed ID: 34384885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CREON (Pancrelipase Delayed-Release Capsules) for the treatment of exocrine pancreatic insufficiency.
    Kuhn RJ; Gelrud A; Munck A; Caras S
    Adv Ther; 2010 Dec; 27(12):895-916. PubMed ID: 21086085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and tolerability of a new formulation of pancrelipase delayed-release capsules in children aged 7 to 11 years with exocrine pancreatic insufficiency and cystic fibrosis: a multicenter, randomized, double-blind, placebo-controlled, two-period crossover, superiority study.
    Graff GR; Maguiness K; McNamara J; Morton R; Boyd D; Beckmann K; Bennett D
    Clin Ther; 2010 Jan; 32(1):89-103. PubMed ID: 20171415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retrospective analysis to investigate the effect of concomitant use of gastric acid-suppressing drugs on the efficacy and safety of pancrelipase/pancreatin (CREON®) in patients with pancreatic exocrine insufficiency.
    Sander-Struckmeier S; Beckmann K; Janssen-van Solingen G; Pollack P
    Pancreas; 2013 Aug; 42(6):983-9. PubMed ID: 23587850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Administration of CREON® pancrelipase pellets via gastrostomy tube is feasible with no loss of gastric resistance or lipase activity: an in vitro study.
    Shlieout G; Koerner A; Maffert M; Forssmann K; Caras S
    Clin Drug Investig; 2011; 31(7):e1-7. PubMed ID: 21627335
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro comparative study of three pancreatic enzyme preparations: dissolution profiles, active enzyme release and acid stability.
    Aloulou A; Puccinelli D; Sarles J; Laugier R; Leblond Y; Carrière F
    Aliment Pharmacol Ther; 2008 Feb; 27(3):283-92. PubMed ID: 17973644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of two enteric coated microsphere preparations in the treatment of pancreatic exocrine insufficiency caused by cystic fibrosis.
    Santini B; Antonelli M; Battistini A; Bertasi S; Collura M; Esposito I; Di Febbraro L; Ferrari R; Ferrero L; Iapichino L; Lucidi V; Manca A; Pisconti CL; Pisi G; Raia V; Romano L; Rosati P; Grazioli I; Melzi G
    Dig Liver Dis; 2000; 32(5):406-11. PubMed ID: 11030186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Experience with the use of 13C-breath test for the evaluation of the efficacy of enzyme substitution therapy with microencapsulated pancreatinin in patients with severe primary pancreatic insufficiency].
    Rapoport SI; Maev IV; Kucheriavyĭ IuA; Shubina NA; Semenova NV; Stukova NIu; Archakov AI
    Klin Med (Mosk); 2009; 87(1):53-7. PubMed ID: 19256262
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of the efficacy and tolerance of pancrelipase and placebo in the treatment of steatorrhea in cystic fibrosis patients with clinical exocrine pancreatic insufficiency.
    Stern RC; Eisenberg JD; Wagener JS; Ahrens R; Rock M; doPico G; Orenstein DM
    Am J Gastroenterol; 2000 Aug; 95(8):1932-8. PubMed ID: 10950038
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An enteric-coated high-buffered pancrelipase reduces steatorrhea in patients with cystic fibrosis: a prospective, randomized study.
    Brady MS; Garson JL; Krug SK; Kaul A; Rickard KA; Caffrey HH; Fineberg N; Balistreri WF; Stevens JC
    J Am Diet Assoc; 2006 Aug; 106(8):1181-6. PubMed ID: 16863712
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bioequivalence study of stressed and nonstressed hard gelatin capsules using amoxicillin as a drug marker and gamma scintigraphy to confirm time and GI location of in vivo capsule rupture.
    Digenis GA; Sandefer EP; Page RC; Doll WJ; Gold TB; Darwazeh NB
    Pharm Res; 2000 May; 17(5):572-82. PubMed ID: 10888309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of oral pancreatic enzymes (Creon 10 capsule) on steatorrhea: a multicenter, placebo-controlled, parallel group trial in subjects with chronic pancreatitis.
    Safdi M; Bekal PK; Martin S; Saeed ZA; Burton F; Toskes PP
    Pancreas; 2006 Aug; 33(2):156-62. PubMed ID: 16868481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In Vitro Comparison of Physical Parameters, Enzyme Activity, Acid Resistance, and pH Dissolution Characteristics of Enteric-Coated Pancreatic Enzyme Preparations: Implications for Clinical Variability and Pharmacy Substitution.
    Kuhn RJ; Eyting S; Henniges F; Potthoff A
    J Pediatr Pharmacol Ther; 2007 Apr; 12(2):115-28. PubMed ID: 23055848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Pancrelipase/Pancreatin in Patients With Exocrine Pancreatic Insufficiency and a Medical History of Diabetes Mellitus.
    Whitcomb DC; Bodhani A; Beckmann K; Sander-Struckmeier S; Liu S; Fuldeore M; Pollack PF; Khurmi RP
    Pancreas; 2016; 45(5):679-86. PubMed ID: 26495784
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative evaluation of the therapeutic efficacy of a pH-sensitive enteric coated pancreatic enzyme preparation with conventional pancreatic enzyme therapy in the treatment of exocrine pancreatic insufficiency.
    Dutta SK; Rubin J; Harvey J
    Gastroenterology; 1983 Mar; 84(3):476-82. PubMed ID: 6549746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomised clinical trial: the efficacy and safety of pancreatin enteric-coated minimicrospheres (Creon 40000 MMS) in patients with pancreatic exocrine insufficiency due to chronic pancreatitis--a double-blind, placebo-controlled study.
    Thorat V; Reddy N; Bhatia S; Bapaye A; Rajkumar JS; Kini DD; Kalla MM; Ramesh H
    Aliment Pharmacol Ther; 2012 Sep; 36(5):426-36. PubMed ID: 22762290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.